Zomepirac sodium salt (McN-2783-21-98) is a potent inhibitor of prostaglandin biosynthesis. Zomepirac sodium salt is a nonsteroidal anti~inflammatory agent (NSAID). Zomepirac sodium salt can cause immune-mediated liver injury.

Physicochemical Properties

Molecular Formula	C₁₅H₁₃CLNNAO₃
Molecular Weight	313.71
Exact Mass	313.048
CAS #	64092-48-4
Related CAS #	33369-31-2 (free acid);64092-48-4 (sodium);64092-49-5 (sodium hydrate);
PubChem CID	16220118
Appearance	Light yellow to yellow solid powder
Boiling Point	470.8ºC at 760 mmHg
Flash Point	238.5ºC
LogP	1.51
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	4
Heavy Atom Count	21
Complexity	385
Defined Atom Stereocenter Count	0
InChi Key	SEEXPXUCHVGZGU-UHFFFAOYSA-M
InChi Code	InChI=1S/C15H14ClNO3.Na/c1-9-7-12(8-13(18)19)17(2)14(9)15(20)10-3-5-11(16)6-4-10;/h3-7H,8H2,1-2H3,(H,18,19);/q;+1/p-1
Chemical Name	sodium;2-[5-(4-chlorobenzoyl)-1,4-dimethylpyrrol-2-yl]acetate
Synonyms	McN-2783-21-98Zomax
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

References

[1]. Hepatic covalent adduct formation with zomepirac in the CD26-deficient mouse. J Gastroenterol Hepatol. 2002 Jan;17(1):66-71. [2]. Evaluation of the analgesic properties of zomepirac. J Clin Pharmacol. 1980 Apr;20(4):216-22.

Solubility Data

Solubility (In Vitro)

DMSO : ~100 mg/mL (~318.77 mM) H2O : ~5 mg/mL (~15.94 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.5 mg/mL (7.97 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.63 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 3: 8.33 mg/mL (26.55 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.1877 mL	15.9383 mL	31.8766 mL
	5 mM	0.6375 mL	3.1877 mL	6.3753 mL
	10 mM	0.3188 mL	1.5938 mL	3.1877 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.